Search Results

Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.

Subjects: COVID-19; COVID-19 pandemic; COVID-19 vaccinesNORTHERN Ireland; WALES; SCOTLAND

• Source: Lancet. Feb2024, Vol. 403 Issue 10426, p554-566. 13p.

Record details

The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia.

• Authors : Català, Martí; Mercadé-Besora, Núria; Kolde, Raivo

Subjects: POST-acute COVID-19 syndrome; VACCINE effectiveness; COVID-19 vaccinesESTONIA; UNITED Kingdom; CATALONIA (Spain)

• Source: Lancet Respiratory Medicine; Mar2024, Vol. 12 Issue 3, p225-236, 12p

Record details

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

• Authors : Zhu, Fengcai; Huang, Shoujie; Liu, Xiaohui

Subjects: COVID-19 vaccines; CLINICAL trials; SARS-CoV-2 Omicron variantFUJIAN Sheng (China)

• Source: Lancet Respiratory Medicine; Dec2023, Vol. 11 Issue 12, p1075-1088, 14p

Record details

Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.

• Authors : Nordström, Peter (AUTHOR); Ballin, Marcel (AUTHOR); Nordström, Anna (AUTHOR)

Subjects: VACCINE effectiveness; COVID-19 vaccines; VACCINATION statusSWEDEN

• Source: Lancet. 2/26/2022, Vol. 399 Issue 10327, p814-823. 10p.

Record details

Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.

• Authors : Wright, Bill J; Tideman, Samuel; Diaz, George A

Subjects: VACCINE effectiveness; BOOSTER vaccines; NUCLEIC acid amplification techniquesPFIZER Inc.; BIONTECH SE

• Source: Lancet Respiratory Medicine; Jun2022, Vol. 10 Issue 6, p557-565, 9p

Record details

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.

• Authors : Payne, Amanda B (AUTHOR); Watts, Janet A (AUTHOR); Mitchell, Patrick K (AUTHOR)

Subjects: OLDER people; VACCINE effectiveness; RESPIRATORY syncytial virus

• Source: Lancet. Oct2024, Vol. 404 Issue 10462, p1547-1559. 13p.

Record details

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.

• Authors : Nyberg, Tommy (AUTHOR); Ferguson, Neil M (AUTHOR); Nash, Sophie G (AUTHOR)

Subjects: SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; BOOSTER vaccines

• Source: Lancet. 4/2/2022, Vol. 399 Issue 10332, p1303-1312. 10p.

Record details

Immunisation status of children adopted from China.

• Authors : Schulpen TWJ (AUTHOR); van Seventer AHJ (AUTHOR); Rümke HC (AUTHOR)

• Source: Lancet. 12/22/2001, Vol. 358 Issue 9299, p2131-2132. 2p.

Record details

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.

• Authors : Butler, Christopher C (AUTHOR); Hobbs, F D Richard (AUTHOR); Gbinigie, Oghenekome A (AUTHOR)

Subjects: MOLNUPIRAVIR; RANDOMIZED controlled trials; COVID-19 treatmentUNITED Kingdom

• Source: Lancet. Jan2023, Vol. 401 Issue 10373, p281-293. 13p.

Record details

Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study.

• Authors : Stock, Sarah J; Moore, Emily; Calvert, Clara

Subjects: SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; PREGNANCY outcomesSCOTLAND

• Source: Lancet Respiratory Medicine; Dec2022, Vol. 10 Issue 12, p1129-1136, 8p

Record details